Entresto — Medical Mutual
Chronic Heart Failure (HF), Adults – continuation of therapy
Reauthorization criteria
- Provider attests that patient achieving clinical benefit while taking Entresto (i.e. decreased hospitalizations, improved heart failure symptoms, improved quality of life, etc); AND
- Entresto is prescribed by or in consultation with a cardiologist; AND
- Entresto is not being used in combination with an ACE inhibitor, an ARB, or aliskiren (Tekturna) in patients with diabetes
Approval duration
1 year